Armistice Capital’s PDS Biotechnology PDSB Stock Holding History

Armistice Capital’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-173,605	Closed	-$105K	–	396
2026 Q1	$105K	Sell	173,605 -2,660,901	-94%	-$2M	﹤0.01%	245
2025 Q4	$2.18M	Buy	+2,834,506	New	+$2.56M	0.03%	158
2025 Q3	–	Sell	-2,236,000	Closed	-$2.97M	–	374
2025 Q2	$2.97M	Sell	2,236,000 -2,183,000	-49%	-$2.96M	0.05%	120
2025 Q1	$5.26M	Buy	+4,419,000	New	+$6.29M	0.08%	112

Other funds holding PDSB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Armistice Capital's PDSB Position: Q2 2026 in Review

Armistice Capital sold out of PDS Biotechnology (PDSB) in Q2 2026, closing a stake of 173,605 shares — an estimated $105K sold.

Armistice Capital first reported a position in PDSB in Q1 2025 and held it in 4 quarters. The position peaked at $5.26M in Q1 2025. 52 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

Armistice Capital reported no remaining PDS Biotechnology position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 173,605 PDS Biotechnology shares in Q2 2026, an estimated $105K.
Armistice Capital first reported a position in PDS Biotechnology in Q1 2025 and held it in 4 quarters.
Armistice Capital's PDS Biotechnology position peaked at $5.26M in Q1 2025.
52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.